Preimplantation Genetic Testing Market Size is projected to reach USD 2.49 Billion by 2030, growing at a CAGR of 9.75%: Straits Research

The global market for preimplantation genetic testing was valued at USD 1.08 billion, and it is anticipated to reach USD 2.49 billion by 2030 with a CAGR of 9.75%. North America was the region that accounted for the most significant revenue share in the global preimplantation genetics diagnosis (PGD) market in 2021

| Source: Straits Research Straits Research

New York, United States, July 27, 2022 (GLOBE NEWSWIRE) -- Preimplantation genetic testing, also known as preimplantation genetic diagnosis, is a procedure for checking for problems in embryos created by in vitro fertilization before being implanted. Preimplantation genetic testing allows doctors to detect flaws in embryos and selectively implant healthy embryos in the uterus, increasing the likelihood of a genetically healthy kid being born.
Preimplantation genetic testing aids people in preventing hereditary illnesses from being passed down through the generations. Preimplantation procedures entail several processes, including collecting eggs from the mother or an egg donor, fertilized in vitro. Following fertilization, fertilized eggs are screened for a variety of genetic disorders.
Unfit embryos are destroyed, whereas healthy embryos can be frozen and saved for later use. Healthy embryos are implanted to induce pregnancy. Preimplantation genetic testing can also be used to determine a woman's gender.
However, there are significant ethical concerns with this application right now. Preimplantation genetic testing is becoming more common as a fertility treatment option among sex-linked genetic condition carriers, single-gene donors, people with chromosomal problems, older women seeking pregnancy, and women who have had many abortions.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/preimplantation-genetic-testing-market/request-sample


Improved Healthcare and Awareness
Demand for better healthcare and higher disposable income create advanced diagnostic and treatment options opportunities. Early diagnostic approaches have acquired importance in healthcare during genetic IVF and other artificial insemination operations to prevent physical malformations and health difficulties in babies. Preimplantation diagnostic testing can detect cystic fibrosis, congenital hearing loss, and thalassemia by examining embryonic genetic differences. Governments and non-profits promote early genetic illness identification to improve women's and children's health.


Birth Malformations Are Rising
Single-gene, mitochondrial, and other gene-related disorders have increased the need for preimplantation diagnostic and screening techniques. According to the state's Department of Health, approximately 1 in 28 newborns in Florida is born with a congenital impairment. PGD is utilized before IVF for a successful pregnancy. PGD is utilized in IVF cycles for women who have experienced several miscarriages or a chromosomally abnormal pregnancy. PGD could help couples with inherited diseases.


Opportunity Growth for The Global Preimplantation Genetic Testing Market   

  • Infertility in Nearly All Women and Genetic Diseases Caused by Chemically Processed Food Consumption

As a result of the incidence of infertility in almost all women and genetic problems caused by chemically processed food consumption, there is potential for the market to grow. As a result, preimplantation genetic treatment is required, lowering the risk of genetic abnormalities and other anomalies in the embryo and aiding in delivering a healthy kid. As a result, preimplantation genetic testing opens many possibilities for genetically engineered kids. There is a potential to use preimplantation genetic testing in this situation. It has a very positive impact on the market.


Regional analysis of the global preimplantation genetic testing market
The market is divided into four regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2021, North America surpassed Europe as the leading region in the Preimplantation Genetics Diagnosis (PGD) market, accounting for most sales. It is due to an increase in the country's population and money spent on healthcare. As of 2019, 489 fertility clinics in the United States provide ART solutions, according to the US Department of Health and Human Services. The states with the highest proportion of ART births are Massachusetts, Columbia, and New Jersey. Furthermore, as people become more aware of healthy embryos in poorer countries, preimplantation genetic diagnosis is likely to become more profitable.
The Europe region is the second-largest market, owing to lifestyle changes and high fertility rates in the United Kingdom, Germany, and Spain.
Despite its smaller size than the top two markets, the Asia Pacific market is expected to grow fastest throughout the projection period. China, India, and Japan are the major Asian-Pacific markets, ascribed to the large population and high fertility rates linked with changing lifestyles, resulting in a demand for preimplantation genetic testing technologies.
Brazil, South Africa, and Saudi Arabia are the market leaders in Latin America and the Middle East. It can be ascribed to these countries' higher healthcare spending.

Report Scope

Report MetricDetails
Market SizeUSD 2.49 Billion by 2030
CAGR9.75%
Historical Data2019-2020
Base Year2021
Forecast Period2022-2030
Forecast UnitsValue (USD Billion)
Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments CoveredProcedure Type, Technology , Product and Service, Application and End-users
Geographies CoveredNorth America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/VendorsOxford Gene Technology, Thermo Fisher Scientific Inc., SciGene Corporation, Agilent Technologies Inc., PerkinElmer Inc., Coopersurgical Inc., Abbott Laboratories, Illumina Inc., Natera Inc, Yikon Genomics
Key Market OpportunitiesThe Healthcare It Industry'S Substantial Growth Fuels The Preimplantation Genetic Testing Market
Key Market DriversImproved medical technologies and a heightened awareness of their importance
An increase in the total number of congenital disorders

Buy Now Full Report @ https://straitsresearch.com/buy-now/preimplantation-genetic-testing-market


Key Highlights

  • The global preimplantation genetic testing market Size was valued at USD 1.08 billion, and it is anticipated to reach USD 2.49 billion by 2030 with a CAGR of 9.75%.
  • The global preimplantation genetic testing market is segmented based on procedure type, product and service, application, end-users and region. Further, based on procedure type, the market is divided into preimplantation genetic diagnosis and preimplantation genetic screening.
  • Based on product & service, the market is divided into Comparative Genomic Hybridization, Single-Nucleotide Polymorphism, Next-Generation Sequencing, Polymerase Chain Reaction, Validation Biomarkers and Fluorescence in Situ Hybridization. The next-generation sequencing segment dominated the market.
  • The application-based segment is divided into Single Gene Disorders, X-Linked Disorders, Aneuploidy, Structural Chromosomal Abnormalities and HLA Typing. The aneuploidy segment dominated the market.
  • According to end-users, the market is divided into hospitals, diagnostic labs and service providers, maternity centres and fertility clinics, and research laboratories and academic institutes. The maternity centres & fertility clinics segment dominated the market.
  • The market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. North America dominates the global market for preimplantation genetic testing.


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/preimplantation-genetic-testing-market/request-sample

Competitive Analysis of the Global Preimplantation Genetic Testing Market

  • Oxford Gene Technology
  • Thermo Fisher Scientific Inc.
  • SciGene Corporation
  • Agilent Technologies Inc.
  • PerkinElmer Inc.
  • Coopersurgical Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • Natera Inc
  • Yikon Genomics 


Segmentation of the Global Preimplantation Genetic Testing Market
By Procedure Type

  • Preimplantation Genetic Diagnosis
  • Preimplantation Genetic Screening

By Technology 

  • Comparative Genomic Hybridization
  • Single-Nucleotide Polymorphism
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Validation Biomarkers
  • Fluorescence in Situ Hybridization

By Product and Service  

  • Instruments                             
  • Reagents and Consumables
  • Software and Services

By Application    

  • Single Gene Disorders
  • X-Linked Disorders         
  • Aneuploidy
  • Structural Chromosomal Abnormalities
  • HLA Typing

By End-users

  • Hospitals, Diagnostic Labs, and Service Providers                 
  • Maternity Centres & Fertility Clinics
  • Research Laboratories & Academic Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America, the Middle East and Africa


TABLE OF CONTENT

  1. Introduction
    1. Market Definition
    2. Market Scope
  2. Research Methodology
    1. Primary Research
    2. Research Methodology
    3. Assumptions & Exclusions
    4. Secondary Data Sources
  3. Market Overview
    1. Report Segmentation & Scope
    2. Value Chain Analysis: Preimplantation Genetic Testing Market
    3. Key Market Trends
      1. Drivers
      2. Restraints
      3. Opportunities
    4. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
    5. Market Share Analysis
  4. Procedure Type Overview
    1. Introduction
      1. Market Size & Forecast
    2. Preimplantation Genetic Diagnosis
      1. Market Size & Forecast
    3. Preimplantation Genetic Screening
      1. Market Size & Forecast
  5. Technology Overview
    1. Introduction
      1. Market Size & Forecast
    2. Validation Biomarkers
      1. Market Size & Forecast
    3. Single-Nucleotide Polymorphism
      1. Market Size & Forecast
  6. Regional Overview
    1. Introduction
      1. Market Size & Forecast
    2. America
      1. North America
      2. U.S.
        1. By Procedure Type
        2. By Technology
      3. Canada
        1. By Procedure Type
        2. By Technology
      4. Mexico
        1. By Procedure Type
        2. By Technology
      5. Latin America
        1. By Procedure Type
        2. By Technology
    3. Europe
      1. Market Size & Forecast
      2. Germany
        1. By Procedure Type
        2. By Technology
      3. France
        1. By Procedure Type
        2. By Technology
      4. U.K.
        1. By Procedure Type
        2. By Technology
      5. Italy
        1. By Procedure Type
        2. By Technology
      6. Spain
        1. By Procedure Type
        2. By Technology
      7. Rest of Europe
        1. By Procedure Type
        2. By Technology
    4. Asia Pacific
      1. Market Size & Forecast
      2. Japan
        1. By Procedure Type
        2. By Technology
      3. China
        1. By Procedure Type
        2. By Technology
      4. Australia
        1. By Procedure Type
        2. By Technology
      5. India
        1. By Procedure Type
        2. By Technology
      6. South Korea
        1. By Procedure Type
        2. By Technology
      7. Rest of Asia-Pacific
        1. By Procedure Type
        2. By Technology
    5. Middle East & Africa
      1. Market Size & Forecast
      2. Saudi Arabia
        1. By Procedure Type
        2. By Technology
      3. South Africa
        1. By Procedure Type
        2. By Technology
      4. Kuwait
        1. By Procedure Type
        2. By Technology
      5. Rest of Middle East & Africa
        1. By Procedure Type
        2. By Technology
  7. Company Profile
    1. Oxford Gene Technology
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
    2. Thermo Fisher Scientific Inc
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
    3. SciGene Corporation
      1. Company Overview
      2. Financial Performance
      3. Recent Developments
      4. Product Portfolio
  8. Conclusion & Recommendation
  9. Acronyms & Abbreviations


Table of Content and Figure @ https://straitsresearch.com/report/preimplantation-genetic-testing-market/toc


Recent Developments in Some of the Key Players

  • April 2022, Illumina Provides Financial Assistance to a Preeminent German Hospital to Improve the Rate of Genetic Disease Diagnosis in Seriously Ill Children.
  • April 2022, Natera, Inc. is a global pioneer in cell-free DNA testing. It has revealed the outcomes of large, real-world research demonstrating a high yield rate for positive genetic findings using the company's RenasightTM test in patients with chronic kidney disease (CKD).

News Media
Medical Device Testing Market to Offer Lucrative Growth Opportunities to the Players During the Forecast Period
Preimplantation Genetic Testing Market to Reach USD 465.1 Million by 2026 at a CAGR of 8.7%
EMC Testing - Global Product Compliance and Certification
North America to the Grab Lion’s Share in the Infectious Disease Testing Market


Have a Look at the Related Research Report               
Blood Testing Market: Information by Test Type (Glucose Testing, Liquid Panel Testing), End-User and Regional Outlook — Forecast Till 2026
Genetic Testing Market: Information by Type (Carrier Testing, Diagnostic Testing), Technology (Cytogenetic Testing), Application (Cancer Diagnosis), and Region — Forecast till 2030
Tuberculosis Testing Market: Information by Diagnostic Test Type (Radiographic Test, Nucleic Acid Testing), End User (Hospital, Clinic, Diagnostics) and, Regional Outlook—Forecast Till 2026


About Straits Research Pvt. Ltd.
StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.


For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)             
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter


Tags

Preimplantation Genetic Genetic Testing Market Preimplantation procedures pregnancy fertility treatment option diagnostic PGD

Related Links